ÂÜÀòÂÒÂ×

David, who joined Ampersand as an Operating Partner in 2015, leads Ampersand’s Portfolio Acceleration Team™ and serves as Chairman of Vivitide. Previously, David was Chairman of Advion Interchim Scientific, and CEO of Advion, sold to Bohui Innovation Technology in 2015. He served as a Board member of Gyros Protein Technologies, sold to Mesa Labs in 2019. David also served as CEO of Advion BioSciences, a bioanalytical CRO business acquired by Quintiles Transnational in 2011, and CEO of Biotage, which was acquired by Pyrosequencing AB in 2003. David holds two separate B.S. degrees from The University of Richmond and Virginia Polytechnic Institute, and completed an International Management program through IMD in Lausanne, Switzerland.